Jose Roques
YOU?
Author Swipe
View article: Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling Open
The cellular and organismal phenotypic response to a small-molecule kinase inhibitor is defined collectively by the inhibitor's targets and their functions. The selectivity of small-molecule kinase inhibitors is commonly determined in …
View article: New mechanisms of resistance to MEK inhibitors in melanoma revealed by intravital imaging
New mechanisms of resistance to MEK inhibitors in melanoma revealed by intravital imaging Open
Targeted therapeutics that are initially effective in cancer patients nearly invariably engender resistance at some stage, an inherent challenge in the use of any molecular-targeted drug in cancer settings. In this study, we evaluated resi…
View article: Table S2 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
Table S2 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling Open
comparison of abemaciclib targets
View article: Supplemental Figure Legends from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
Supplemental Figure Legends from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling Open
Supplemental Figure Legends
View article: Figure S2 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
Figure S2 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling Open
Abemeciclib competitive MIB/MS TMT dose response
View article: Figure S1 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
Figure S1 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling Open
Dasatinib and BMS777607 competitive MIBMS
View article: Supplemental Figure Legends from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
Supplemental Figure Legends from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling Open
Supplemental Figure Legends
View article: Table S1 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
Table S1 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling Open
MIB/MS data
View article: Table S1 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
Table S1 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling Open
MIB/MS data
View article: Data from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
Data from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling Open
The cellular and organismal phenotypic response to a small-molecule kinase inhibitor is defined collectively by the inhibitor's targets and their functions. The selectivity of small-molecule kinase inhibitors is commonly determined in v…
View article: Table S2 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
Table S2 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling Open
comparison of abemaciclib targets
View article: Figure S2 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
Figure S2 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling Open
Abemeciclib competitive MIB/MS TMT dose response
View article: Figure S1 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
Figure S1 from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling Open
Dasatinib and BMS777607 competitive MIBMS
View article: Data from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
Data from Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling Open
The cellular and organismal phenotypic response to a small-molecule kinase inhibitor is defined collectively by the inhibitor's targets and their functions. The selectivity of small-molecule kinase inhibitors is commonly determined in v…
View article: Sup Fig 4 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig 4 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
MEKi Experiment Overview
View article: Sup Fig Legends from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig Legends from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
Sup Fig Legends
View article: Sup Fig 6 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig 6 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
mRNAseq pathway signature analysis reveals gene expression reprogramming on MEKi.
View article: Sup Fig 5 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig 5 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
Expanded detail on MIB MS experiment
View article: Sup Fig 8 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig 8 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
Graphical representation and model of results
View article: Sup Fig Legends from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig Legends from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
Sup Fig Legends
View article: Sup Fig 6 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig 6 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
mRNAseq pathway signature analysis reveals gene expression reprogramming on MEKi.
View article: Sup Fig 1 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig 1 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
Achievement of reproducible spatial and temporal control of melanoma growth with
View article: Sup Fig 3 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig 3 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
Structural reorganization and amelanotic intratumoral nests are evident in persistent melanoma on MEKi.
View article: Data from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Data from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
Targeted therapeutics that are initially effective in cancer patients nearly invariably engender resistance at some stage, an inherent challenge in the use of any molecular-targeted drug in cancer settings. In this study, we evaluated resi…
View article: Sup Fig 7 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig 7 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
Kinome and transcriptome responses to combined BRAF and MEK inhibition in murine tumors, patient samples, and human cell lines
View article: Sup Fig 2 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig 2 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
BRAFV600E and PTEN-loss are required for tumor growth, which is temporally controlled and reproducible at the cell level.
View article: Sup Fig 8 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig 8 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
Graphical representation and model of results
View article: Sup Fig 5 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig 5 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
Expanded detail on MIB MS experiment
View article: Sup Fig 2 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig 2 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
BRAFV600E and PTEN-loss are required for tumor growth, which is temporally controlled and reproducible at the cell level.
View article: Sup Fig 3 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Sup Fig 3 from New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging Open
Structural reorganization and amelanotic intratumoral nests are evident in persistent melanoma on MEKi.